Just when Admedus shareholders were starting to smile again, the grin was wiped off their faces by the announcement of another capital raising on the 10th May 2018. The share price, after reaching an anticipated 38 cents, plummeted that day… Read More ›
https://technicality.me/2018/03/08/admedus-adapt-products-gaining-market-traction/ I trust readers will forgive me for another post on this emerging global health-care stock, Admedus. I keep coming back to it for subject matter, not to “ramp” it up, but rather to focus my attention on how its… Read More ›
Australian small-cap healthcare stock Admedus now has a calendar year reporting season, and on the 28th February 2018 it accordingly announced its financial results for the second half of 2017, covering the period 30 June to 31 December 2017. Admedus has… Read More ›
The daily chart above displays the price action of emerging health-care stock Admedus, a stock I have frequently reviewed over the past 5 years on this blog. It has promised much, but the share-price has gone nowhere in that time,… Read More ›
This is another chart of Admedus, a Healthcare stock I have followed and frequently posted about, over the past 4 years. I acknowledge that I am a shareholder, and therefore have a pecuniary interest in the stock, but I have… Read More ›
Security selection is easy for traders. Almost any market/security will do. So long as it is moving. Their problem is to determine the direction of movement, capture the trend, and exit before it changes. It may sound easy but… Read More ›
The share price of Admedus, a specialist healthcare company in which the writer has been invested for more than three years, today spiked 20% higher from last week’s close at 32.5 cents. It gapped higher at the open on news… Read More ›
What the charts don’t disclose! Charts do not lie. They are objective. They reflect market perceptions, but do not disclose the myriad of influences determining that sentiment, nor do they necessarily impart a balanced view of the chances of ongoing… Read More ›
This week marked the third anniversary of my holding in the biotech stock Admedus. I have shared with readers its fluctuating fortunes in this time, striving to present its prospects in as objective a manner as possible. I have taken… Read More ›
Technically Speaking 